Goldman Sachs
MRNA icon

Goldman Sachs’s Moderna MRNA Stock Holding History

Goldman Sachs’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-167,000
Closed -$8.48M – 6849
2026
Q1 		$8.48M Sell
167,000
-1,579,300
-90% -$73.7M ﹤0.01% 3199
2025
Q4 		$51.5M Buy
+1,746,300
New +$47.4M 0.01% 1487
2025
Q1 		– Sell
-128,500
Closed -$5.34M – 6299
2024
Q4 		$5.34M Sell
128,500
-25,000
-16% -$1.19M ﹤0.01% 3392
2024
Q3 		$10.3M Sell
153,500
-5,400
-3% -$496K ﹤0.01% 2692
2024
Q2 		$18.9M Buy
158,900
+38,900
+32% +$4.92M ﹤0.01% 1937
2024
Q1 		$12.8M Sell
120,000
-117,000
-49% -$11.8M ﹤0.01% 2255
2023
Q4 		$23.6M Buy
237,000
+97,600
+70% +$8.21M ﹤0.01% 1751
2023
Q3 		$14.4M Sell
139,400
-15,600
-10% -$1.74M ﹤0.01% 2071
2023
Q2 		$18.8M Buy
155,000
+70,000
+82% +$9.34M ﹤0.01% 1905
2023
Q1 		$13.1M Sell
85,000
-150,300
-64% -$24.8M ﹤0.01% 2177
2022
Q4 		$42.3M Buy
235,300
+114,500
+95% +$18.7M 0.01% 1310
2022
Q3 		$14.3M Buy
120,800
+27,500
+29% +$4.17M ﹤0.01% 2166
2022
Q2 		$13.3M Sell
93,300
-150,400
-62% -$21.5M ﹤0.01% 2235
2022
Q1 		$42M Buy
243,700
+151,400
+164% +$25.5M 0.01% 1427
2021
Q4 		$23.4M Buy
92,300
+68,300
+285% +$20M ﹤0.01% 1973
2021
Q3 		$9.24M Sell
24,000
-180,000
-88% -$66.4M ﹤0.01% 2806
2021
Q2 		$47.9M Buy
204,000
+84,000
+70% +$15M 0.01% 1297
2021
Q1 		$15.7M Buy
120,000
+60,000
+100% +$8.69M ﹤0.01% 2145
2020
Q4 		$6.27M Sell
60,000
-23,600
-28% -$2.39M ﹤0.01% 2847
2020
Q3 		$5.92M Sell
83,600
-68,400
-45% -$4.77M ﹤0.01% 2765
2020
Q2 		$9.76M Buy
152,000
+143,300
+1,647% +$7.85M ﹤0.01% 2293
2020
Q1 		$261K Buy
+8,700
New +$200K ﹤0.01% 4584

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Goldman Sachs's MRNA Position: Q2 2026 in Review

Goldman Sachs reduced its Moderna (MRNA) stake by 29% in Q2 2026, selling an estimated $99.9M and leaving 4,671,950 shares worth $327M. The position accounts for 0.03% of the portfolio, ranked #558.

Goldman Sachs first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $610M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Goldman Sachs held 4,671,950 shares of Moderna worth $327M as of Q2 2026.
  • Goldman Sachs sold 1,931,747 Moderna shares in Q2 2026, an estimated $99.9M.
  • Moderna made up 0.03% of Goldman Sachs's portfolio in Q2 2026, its #558 holding.
  • Goldman Sachs first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
  • Goldman Sachs's Moderna position peaked at $610M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.